Skip to main content

Table 3 RAND SF-36 at baseline, six months, and baseline-six months

From: Placebo-controlled randomized clinical trial of fish oil’s impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus

 

Placebo (N=14)

Fish oil (N=18}

Mann–Witney U

 

Median [IQR]

Median [IQR]

p-value

Baseline

   

 Physical functioning

75.00 [52.90–90.00]

32.5 [17.50–55.00]

.004

 Role functioning/physical

75.00 [0.00–100.00]

0.00 [0.00–25.00]

.022

 Role functioning/emotional

66.67 [0.00–100.00]

0.00 [0.00–16.67]

.021

 Energy/fatigue

55.00 [28.75–76.25]

20.00 [10.00–46.25]

.016

 Emotional well-being

68.00 [60.00–89.00]

40.00 [28.00–64.00]

.006

 Social functioning

68.75 [46.88–90.63]

37.50 [21.88–62.50]

.006

 Pain

62.50 [45.00–92.50]

22.50 [9.38–47.50]

.001

 General health

42.50 [28.75–62.50]

30 [18.75–50.00]

.100

Six Months

   

 Physical functioning

77.50 [48.75–96.25]

30.00 [15.00–51.25]

.005

 Role functioning/ physical

75.00 [43.75–100.00]

0.00 [0.00–75.00]

.015

 Role functioning/ emotional

100.00 [50.00–100.00]

16.67 [0.00–100.00]

.217

 Energy/fatigue

55.00 [32.50–70.00]

37.50 [20.00–56.25]

.138

 Emotional well-being

78.00 [61.00–88.00]

66.00 [44.00–77.00]

.037

 Social functioning

68.75 [50.00–100.00]

50.00 [25.00–75.00]

.023

 Pain

72.50 [46.25–92.50]

32.5 [22.50–57.50]

.009

 General health

52.50 [20.00–60.00]

37.50 [30.00–51.25]

.380

Six Months-Baseline

   

 Physical functioning

5.00 [-10.00–21.25]

-2.50 [-10.00–16.25]

.468

 Role functioning/physical

0.00 [0.00–25.00]

0.00 [0.00–25.00]

.878

 Role functioning/emotional

0.00 [0.00–33.33]

0.00 [0.00–50.00]

.693

 Energy/fatigue

-2.50 [-6.25–11.25]

10.00 [-1.25–21.25]

.092

 Emotional well-being

4.00 [-5.00–14.00]

16.00 [-1.00–33.00]

.070

 Social functioning

6.25 [-9.38–18.75]

6.25 [-12.50–37.50]

.657

 Pain

-11.25 [-14.38–18.13]

10.00 [0.00–25.00]

.105

 General health

-2.50 [-10.00–6.25]

5.00 [-11.25–23.75]

.312

  1. RAND SF-36 data are presented as median and interquartile range (IQR) for all completer patients at baseline, study completion, and difference between baseline and six months